<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448018</url>
  </required_header>
  <id_info>
    <org_study_id>2009-011403-23</org_study_id>
    <nct_id>NCT01448018</nct_id>
  </id_info>
  <brief_title>Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion</brief_title>
  <acronym>CHIC-3</acronym>
  <official_title>Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare ranibizumab injection to hemodilution at the early
      phase of Central Retinal Vein Occlusion (CRVO) and to determine if the combination of both
      treatments may have a synergic effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with recent-onset CRVO (lasting for less than 1 month)are randomly assigned to one
      of 3 groups: hemodilution using erythrocytapheresis alone, 3 monthly injection of ranibizumab
      alone, or both.

      Patients are followed monthly during the 6-month study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in best-corrected visual acuity (ETDRS chart) between baseline and 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gain in visual acuity of 2 ETDRS-lines or more</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients who gained 2 lines or more between baseline and the 6-month visit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this arm receive 3 monthly injection of ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodilution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranibizumab and hemodilution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive both treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>3 monthly intravitreous injection as soon as possible after the inclusion</description>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_label>ranibizumab and hemodilution</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemodilution</intervention_name>
    <description>hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion</description>
    <arm_group_label>Hemodilution</arm_group_label>
    <arm_group_label>ranibizumab and hemodilution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CRVO confirmed by fluorescein angiography

          -  duration from onset of 1 month or less

          -  visual acuity of 20/32 or less

        Exclusion Criteria:

          -  neovascular complication

          -  extensive retinal ischemia requiring prompt panretinal photocoagulation

          -  hematocrit level lower than 38%

          -  previous laser or surgery in the study eye, etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Intercommunal Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie-Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Glacet-Bernard A, Atassi M, Fardeau C, Romanet JP, Tonini M, Conrath J, Denis P, Mauget-Faÿsse M, Coscas G, Soubrane G, Souied E. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):505-12. doi: 10.1007/s00417-010-1532-5. Epub 2010 Oct 17.</citation>
    <PMID>20953877</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Agnes Glacet-Bernard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

